vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Tempus AI, Inc. (TEM). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $367.2M, roughly 1.3× Tempus AI, Inc.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -14.8%, a 4.6% gap on every dollar of revenue. On growth, Tempus AI, Inc. posted the faster year-over-year revenue change (83.0% vs 44.7%). Tempus AI, Inc. produced more free cash flow last quarter ($-41.5M vs $-69.0M). Over the past eight quarters, Tempus AI, Inc.'s revenue compounded faster (58.7% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

CLOV vs TEM — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.3× larger
CLOV
$487.7M
$367.2M
TEM
Growing faster (revenue YoY)
TEM
TEM
+38.2% gap
TEM
83.0%
44.7%
CLOV
Higher net margin
CLOV
CLOV
4.6% more per $
CLOV
-10.1%
-14.8%
TEM
More free cash flow
TEM
TEM
$27.4M more FCF
TEM
$-41.5M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
TEM
TEM
Annualised
TEM
58.7%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
TEM
TEM
Revenue
$487.7M
$367.2M
Net Profit
$-49.3M
$-54.2M
Gross Margin
Operating Margin
-10.1%
-16.7%
Net Margin
-10.1%
-14.8%
Revenue YoY
44.7%
83.0%
Net Profit YoY
-123.2%
-316.2%
EPS (diluted)
$-0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
TEM
TEM
Q4 25
$487.7M
$367.2M
Q3 25
$496.6M
$334.2M
Q2 25
$477.6M
$314.6M
Q1 25
$462.3M
$255.7M
Q4 24
$337.0M
$200.7M
Q3 24
$331.0M
$180.9M
Q2 24
$356.3M
$166.0M
Q1 24
$346.9M
$145.8M
Net Profit
CLOV
CLOV
TEM
TEM
Q4 25
$-49.3M
$-54.2M
Q3 25
$-24.4M
$-80.0M
Q2 25
$-10.6M
$-42.8M
Q1 25
$-1.3M
$-68.0M
Q4 24
$-22.1M
$-13.0M
Q3 24
$-9.2M
$-75.8M
Q2 24
$7.4M
$-552.2M
Q1 24
$-19.2M
$-64.7M
Gross Margin
CLOV
CLOV
TEM
TEM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
TEM
TEM
Q4 25
-10.1%
-16.7%
Q3 25
-4.9%
-18.3%
Q2 25
-2.2%
-19.6%
Q1 25
-0.3%
-26.9%
Q4 24
-6.4%
-25.3%
Q3 24
-2.7%
-29.6%
Q2 24
2.0%
-321.4%
Q1 24
-6.5%
-36.5%
Net Margin
CLOV
CLOV
TEM
TEM
Q4 25
-10.1%
-14.8%
Q3 25
-4.9%
-23.9%
Q2 25
-2.2%
-13.6%
Q1 25
-0.3%
-26.6%
Q4 24
-6.6%
-6.5%
Q3 24
-2.8%
-41.9%
Q2 24
2.1%
-332.7%
Q1 24
-5.5%
-44.4%
EPS (diluted)
CLOV
CLOV
TEM
TEM
Q4 25
$-0.30
Q3 25
$-0.46
Q2 25
$-0.25
Q1 25
$-0.40
Q4 24
$2.56
Q3 24
$-0.46
Q2 24
$-6.86
Q1 24
$-1.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
TEM
TEM
Cash + ST InvestmentsLiquidity on hand
$78.3M
$604.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$491.3M
Total Assets
$541.0M
$2.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
TEM
TEM
Q4 25
$78.3M
$604.8M
Q3 25
$655.9M
Q2 25
$186.3M
Q1 25
$151.6M
Q4 24
$194.5M
$341.0M
Q3 24
$288.0M
$388.0M
Q2 24
$254.8M
$478.8M
Q1 24
$208.3M
$79.9M
Stockholders' Equity
CLOV
CLOV
TEM
TEM
Q4 25
$308.7M
$491.3M
Q3 25
$340.9M
$507.8M
Q2 25
$344.2M
$309.6M
Q1 25
$336.1M
$326.2M
Q4 24
$341.1M
$56.3M
Q3 24
$342.2M
$53.7M
Q2 24
$324.9M
$98.3M
Q1 24
$292.5M
$-1.5B
Total Assets
CLOV
CLOV
TEM
TEM
Q4 25
$541.0M
$2.3B
Q3 25
$559.7M
$2.3B
Q2 25
$575.0M
$1.6B
Q1 25
$583.7M
$1.5B
Q4 24
$580.7M
$926.1M
Q3 24
$653.0M
$971.7M
Q2 24
$674.2M
$864.6M
Q1 24
$671.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
TEM
TEM
Operating Cash FlowLast quarter
$-66.9M
$-36.8M
Free Cash FlowOCF − Capex
$-69.0M
$-41.5M
FCF MarginFCF / Revenue
-14.1%
-11.3%
Capex IntensityCapex / Revenue
0.4%
1.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-239.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
TEM
TEM
Q4 25
$-66.9M
$-36.8M
Q3 25
$12.1M
$-119.8M
Q2 25
$5.4M
$44.2M
Q1 25
$-16.3M
$-105.6M
Q4 24
$34.8M
Q3 24
$50.0M
$48.7M
Q2 24
$44.8M
$-97.1M
Q1 24
$25.9M
$-101.4M
Free Cash Flow
CLOV
CLOV
TEM
TEM
Q4 25
$-69.0M
$-41.5M
Q3 25
$11.4M
$-126.5M
Q2 25
$4.8M
$36.6M
Q1 25
$-16.5M
$-107.7M
Q4 24
$33.3M
Q3 24
$49.6M
$48.6M
Q2 24
$44.4M
$-105.1M
Q1 24
$25.5M
$-107.5M
FCF Margin
CLOV
CLOV
TEM
TEM
Q4 25
-14.1%
-11.3%
Q3 25
2.3%
-37.9%
Q2 25
1.0%
11.6%
Q1 25
-3.6%
-42.1%
Q4 24
9.9%
Q3 24
15.0%
26.9%
Q2 24
12.5%
-63.3%
Q1 24
7.3%
-73.7%
Capex Intensity
CLOV
CLOV
TEM
TEM
Q4 25
0.4%
1.3%
Q3 25
0.1%
2.0%
Q2 25
0.1%
2.4%
Q1 25
0.0%
0.8%
Q4 24
0.5%
Q3 24
0.1%
0.0%
Q2 24
0.1%
4.8%
Q1 24
0.1%
4.2%
Cash Conversion
CLOV
CLOV
TEM
TEM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons